Inactive Instrument

GINO BIOW Share Price Nasdaq

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 199M 16.64B Sales 2025 * 265M 22.1B Capitalization 1.68B 141B
Net income 2024 * -569M -47.52B Net income 2025 * -479M -40B EV / Sales 2024 * 5.37 x
Net cash position 2024 * 613M 51.21B Net cash position 2025 * 557M 46.51B EV / Sales 2025 * 4.25 x
P/E ratio 2024 *
-2.69 x
P/E ratio 2025 *
-3.13 x
Employees 1,218
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.67%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 01/08/01
Founder - 01/08/01
Founder 43 01/08/01
Members of the board TitleAgeSince
Director/Board Member 56 16/21/16
Director/Board Member 74 01/21/01
Chairman 65 16/21/16
More insiders
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW